Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Biotechnology
With so much of the exciting data at ASCO 2017 again surrounding cancer immunotherapies, The Pharma Letter finds confidence that more will follow in the footsteps of Merck & Co's Keytruda (pembrolizumab). 8 June 2017
Pharmaceutical
In 2015, costs of prescription drugs in the USA increased by 13.5%.1 If this trend continues, all branded pharmaceuticals will have 100% increase in their prices in ten years’ time. This steep escalation in drug prices will not only affect consumers, but also insurance companies who will eventually raise their premium prices to cover the additional cost, says Dr Nicola Davies in her exclusive monthly blog for The Pharma Letter. 7 June 2017
Pharmaceutical
Mylan is fighting battles on multiple fronts, including over price increases of its EpiPen (epinephrine) devices and as it races to market with its biosimilar products. 7 June 2017
Generics
Just 14 months after taking the reins at Perrigo, John Hendrickson is to retire from his position as chief executive at the Ireland-incorporated generics drugmaker. 6 June 2017
Biotechnology
Dutch human gene therapy specialist uniQure (Nasdaq: QURE) has named Steven Zelenkofske as chief medical officer, effective immediately. 6 June 2017
Biotechnology
The American arm of the independent Swiss biotech company Octapharma has appointed Richard Walters as its new vice president of commercial development. 5 June 2017
Pharmaceutical
The Union for Affordable Cancer Treatment (UACT), along with 56 other organizations, has requested the Regents of the University of California (UCLA) to withdraw its efforts before the Delhi High Court to obtain a patent on prostate cancer drug Xtandi (enzalutamide) in India, reports The Pharma Letter’s India correspondent. 5 June 2017
Biotechnology
David Stamler has joined Australia’s Prana Biotechnology as chief medical officer and senior vice president, clinical development, based in San Francisco. 5 June 2017
Biotechnology
As the annual meeting of the American Society of Clinical Oncology gets underway in Chicago, investors, competitors and industry watchers eagerly await results of Janssen’s LATITUDE trial of Zytiga in prostate cancer. 2 June 2017
Pharmaceutical
Privately-held Swiss firm Ferring Pharmaceuticals today announced that Paul Navarre has been appointed chief executive of Ferring Holding Inc. 2 June 2017
Pharmaceutical
In our latest ASCO-themed expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, discusses why the oncology sector is seeing increased M&A activity and offers advice to buyers and sellers on how to maximize opportunities in the market and complete deals on the most favorable terms. 2 June 2017
Biosimilars
With data on so many innovative but expensive new oncology treatments being presented at ASCO 2017, it is a crucial period for biosimilars of three of the world's biggest-selling cancer drugs to deliver their promised savings, and this feature looks at the progress of these copycat biologics in reaching markets and patients. 1 June 2017
Biotechnology
Silence Therapeutics has recruited Torsten Hoffmann as chief operating officer, reporting directly to Ali Mortazavi, chief executive. This is not a plc board appointment. 1 June 2017
Pharmaceutical
Germany’s Merck KGaA has not appeared near the summit of any rankings on top pharma companies by oncology revenue in recent years, with earnings from its sole cancer product Erbitux (cetuximab) dropping to below $1 billion in 2016. 31 May 2017
Biotechnology
A cloud is hanging over UK-registered biotech Akari Therapeutics after inaccuracies came to light in a trial comparing its lead product to a rival drug and questions arose over the role of its chief executive in a related report. 31 May 2017
Biotechnology
Ireland-incorporated biotech firm Alkermes has named Craig Hopkinson to the posts of chief medical officer, and senior vice president of clinical development and medical affairs. 31 May 2017
Pharmaceutical
In a column being published first in The Pharma Letter, Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), looks at how the life sciences industry is working together to tackle antimicrobial resistance. 30 May 2017
Generics
Even as India’s National Pharmaceutical Pricing Authority (NPPA) has fixed the prices of 31 more drug formulations, in yet another crackdown on prices, India's premier policy formulating agency Niti Aayog has proposed a change in the manner the government should identify drugs to be brought under price control. 26 May 2017
Biotechnology
Speaking with The Pharma Letter ahead of the upcoming annual meeting of the American Society of Clinical Oncology, Michael Pehl says that: “We are really excited about the event - we have a really broad range of clinical data.” 26 May 2017
Generics
Global drugmakers operating in Russia have called on the country’s government to impose a ban on the registration of generics before the expiration of the patent protection of original drugs. 25 May 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze